Frédéric Joliot Institute for Life Sciences - Sur le même thème https://joliot.cea.fr/drf/joliot/en/Pages/news/Institute/2021/Deeptope-start-up-Simos.aspx Website of the Frédéric-Joliot Institute of Life Sciences which includes 4 departments: I2BC, DMTS, NeuroSpin and Service hospitalier Frédéric Joliot (SHFJ). The teams are mainly located at the CEA Paris-Saclay center and at the Orsay hospital. en-US https://www.cea.frhttps://www-cea-fr.admsite.extra.cea.fr/Style%20Library/Themes/drf/instituts/images/logo-cea-joliot.png Frédéric Joliot Institute for Life Sciences - Sur le même thème https://joliot.cea.fr/drf/joliot/en Functionalization of the B subunit of Shiga toxin as a vaccine tool https://www.cea.fr/drf/joliot/en/Pages/news/Science/2024/Functionalization-B-subunit-Shigatoxin-vaccine-tool.aspx Researchers at SIMoS (DMTS) describe the synthesis, engineering and evaluation of the properties of the B subunit of bacterial Shiga toxin (STxB), administered mucosally, as a vaccine tool. Their results confirm the value of using a synthetic STxB in an anti-tumor and anti-infectious vaccination strategy. Biotechnology ; Vaccine SIMOPRO Scientific result préclinique; Fri, 26 Jan 2024 11:00:00 GMT Click-Chemistry: optimized drug delivery from nanomicelles into tumor cells https://www.cea.fr/drf/joliot/en/Pages/news/Science/2023/Click-Chemistry-optimized-drug-delivery-nanomicelles.aspx Researchers at SCBM have used a click-and-release chemistry approach to mass-release an anti-cancer drug into cells from cleavable nanomicelles, thanks to a bioorthogonal activation process. A step towards the development of new nanomedicines Chemistry ; Biotechnology SCBM Scientific result Fri, 10 Nov 2023 11:00:00 GMT Impact of metabolic variations on PET imaging of neuroinflammation in humans https://www.cea.fr/drf/joliot/en/Pages/news/Science/2023/Impact-metabolism-PET-imaging-neuroinflammation.aspx Researchers at BioMaps evaluated the effect of several factors on the distribution of [18F]DPA-714 in 201 subjects who participated in SHFJ PET imaging protocols to better understand the role of neuroinflammation in various neurological diseases. They conclude that measures of individual metabolism are important in image interpretation. Positron Emission Tomography ; Medical imaging ; Pharmacology SHFJ Scientific result Thu, 12 Oct 2023 10:00:00 GMT Exploring the potential of a model cyanobacterium for the photosynthetic production of high-value terpenes https://www.cea.fr/drf/joliot/en/Pages/news/Science/2023/Model-cyanobacterium-production-high-value-terpenes.aspx Through two publications, an I2BC team demonstrates the high biotechnological potential of the model cyanobacterium Synechocystis PCC 6803 for the photosynthetic production of high value-added organic compounds, the terpenes. Photosynthesis ; Microalgae ; Biotechnology SB2SM Scientific result Fri, 10 Feb 2023 11:00:00 GMT From a marine toxin to a melanocortin receptor antagonist, a therapeutic target for energy metabolism disorders https://www.cea.fr/drf/joliot/en/Pages/news/Science/2023/Cone-marine-toxin-melanocortin-receptor-antagonist.aspx A SIMoS team discovered a toxin in the venom of a marine cone that it engineers into a high affinity antagonistic peptide for the melanocortin receptor, a major regulator of energy homeostasis. A step towards the development of innovative treatments for certain eating disorders Pharmacology ; High-throughput screening ; Proteomics ; Transcriptomics SIMOPRO Scientific result Thu, 09 Feb 2023 11:00:00 GMT Discovery of a natural peptide from black mamba venom, with anticholinergic properties https://www.cea.fr/drf/joliot/en/Pages/news/Science/2022/Discovery-natural-peptide-black-mamba-venom.aspx ​A team from SIMoS (DMTS) identifies and characterizes a toxin isolated from black mamba venom, whose specific anticholinergic properties at the type 2 acetylcholine receptor, a regulator of arterial tone, position it as a potential drug candidate for the treatment of cardiovascular diseases. Health & life sciences ; Biotechnology SIMOPRO Scientific result ; Article Mon, 21 Nov 2022 11:00:00 GMT Molecular engineering of antibodies to accommodate antigenic drift of SARS-CoV-1 and 2 https://www.cea.fr/drf/joliot/en/Pages/news/Science/2022/Engineering-antibodies-accommodate-antigenic-drift-SARS-CoV-1-2.aspx Researchers from SIMoS and SPI (DMTS) demonstrate that molecular engineering of llama antibodies, capable of neutralizing SARS-CoV-1, allows to obtain optimized antibodies with very high affinities for SARS-CoV-2 and its variants, the culprits of the Covid-19 epidemic. Biotechnology ; Virus SPI Scientific result Thu, 22 Sep 2022 10:00:00 GMT Dual labeling and digital imaging for the evaluation of protein-drug conjugates in preclinical models https://www.cea.fr/drf/joliot/en/Pages/news/Science/2022/In-vivo-evaluation-antibody-drug-conjugate.aspx A team from SIMoS, in collaboration with the SCBM (DMTS), has developed an original bioanalytical approach based on the double 14C-3H isotopic labeling of an antibody-drug conjugate, allowing the simultaneous in vivo monitoring of the two components in mouse models as well as their precise quantification in the organs. Pharmacology ; Cell and molecular imaging SIMOPRO Scientific result Mon, 22 Aug 2022 10:00:00 GMT How to make biodrugs less immunogenic? Answer with a monoclonal antibody with anti-inflammatory properties https://www.cea.fr/drf/joliot/en/Pages/news/Science/2022/How-to-make-biodrugs-less-immunogenic.aspx SIMoS team, in collaboration with Bicêtre Hospital, shows that certolizumab pegol, a pegylated monoclonal antibody fragment for anti-inflammatory use, is less likely to trigger an adverse immune response than the non-pegylated form. Health & life sciences ; Biotechnology SIMOPRO Scientific result Mon, 20 Jun 2022 10:00:00 GMT Buprenorphine/benzodiazepine interaction: why is it more dangerous? https://www.cea.fr/drf/joliot/en/Pages/news/Science/2022/Interaction-buprenorphine-benzodiazepine.aspx ​A collaboration between the SHFJ and the UMR-S 1144 (University of Paris) shows that the deleterious effect of the buprenorphine/benzodiazepine combination would result from the combined action of each drug on its target. Diagnosis and innovative treatment ; Pharmacology Researchers SHFJ Scientific result ; Article pharmacodynamics;opioids; Fri, 25 Mar 2022 11:00:00 GMT Deeptope: accelerating the development of therapeutic antibodies via high-throughput functional tests https://www.cea.fr/drf/joliot/en/Pages/news/Institute/2021/Deeptope-start-up-Simos.aspx Deeptope, founded in February 2021 from a technology developed at the DMTS Laboratory of Cellular Immunology and Biotechnology (LICB), is a company of therapeutic antibody engineering that provides antibody optimization and characterization services to biotech or pharmaceutical firms with the goal of increasing the quality of antibodies in a very short timeframe. Biotechnology ; Pharmacology News ; Article Mon, 29 Nov 2021 11:00:00 GMT Evaluation of the immunogenicity of peptide-drugs containing non-natural modifications https://www.cea.fr/drf/joliot/en/Pages/news/Science/2021/Immunogenicity-therapeutic-peptides.aspx A team from SIMoS (DMTS) in collaboration with Sanofi shows that the introduction of non-natural sequences into an immunogenic peptide attenuates the immune response against this peptide, an approach that could guide the design of less immunogenic, and therefore more effective, therapeutic peptides. Health & life sciences ; Pharmacology Scientific result Tue, 01 Jun 2021 10:00:00 GMT PET imaging reveals the neuropharmacology of buprenorphine https://www.cea.fr/drf/joliot/en/Pages/news/Science/2021/PETimaging-neuropharmacology-buprenorphine.aspx Researchers at BioMaps (SHFJ) have succeeded in determining the interaction dynamics of buprenorphine, an opioid drug with a particularly complex pharmacology, with its brain receptors in vivo. To do so, they developed an original PET imaging approach based on the use of the radiolabeled molecule (11C-buprenorphine). Brain ; Positron Emission Tomography ; Pharmacology Scientific result Wed, 05 May 2021 10:00:00 GMT How works Mambalgin-1, an analgesic peptide from black mamba venom https://www.cea.fr/drf/joliot/en/Pages/news/Science/2021/How-works-Mambalgin-1.aspx Teams from IPMC and SIMoS (DMTS) defined the molecular determinants of the interaction between Mambalgin-1, an analgesic peptide isolated from black mamba venom, and its target, ASIC1 (Acid-Sensing Ion Channels), to model, using molecular dynamics, this complex. The resulting model provides clues to develop blockers of ASIC1, interesting targets for clinical pain relief applications. Pharmacology Scientific result Thu, 08 Apr 2021 10:00:00 GMT Synthetic biology: new tools to increase the diversity of the 2,5-diketopiperazines produced in E.coli https://www.cea.fr/drf/joliot/en/Pages/news/Science/2020/Synthetic-biology-increase-diversity-diketopiperazines.aspx Researchers from I2BC (SBIGeM), in collaboration with teams from Sorbonne University, have characterized cyclodipeptide oxidases in vivo and shown that they are valuable tools for producing dehydrogenated 2,5-diketopiperazines, precursors of bioactive molecules of pharmaceutical interest, in Escherichia coli using synthetic biology approaches. Fundamental Research ; Health & life sciences ; Biotechnology Scientific result Fri, 25 Sep 2020 10:00:00 GMT Magnetic sensors for ultra-sensitive biochips https://www.cea.fr/drf/joliot/en/Pages/news/Science/2020/Magnetic-sensors-ultra-sensitive-biochips.aspx Researchers from IRAMIS collaborated with a team from SPI (LERI) for the development of a microfluidic biochip ("lab-on-chip") based on ultra-sensitive magnetic sensors with giant magnetoresistance (GMR sensors), capable of individually and effectively detect magnetically-labeled biological targets. Biotechnology ; Biodetection ; Physics Scientific result Wed, 08 Jan 2020 11:00:00 GMT A ferredoxin to fuel metabolic pathways of biotechnological interest https://www.cea.fr/drf/joliot/en/Pages/news/Science/2019/A-ferredoxin-to-fuel-metabolic-pathways.aspx Researchers at BIAM and I2BC@Saclay, in collaboration with Japanese colleagues from Okayama University and Ehime, have characterized in a cyanobacterium a minor protein that diverts part of the energy from photosynthesis to secondary metabolic pathways. This discovery is promising to exploit these metabolic pathways in a biotechnological process of bioenergy production. Biotechnology ; Bioenergy ; Photosynthesis Scientific result Mon, 14 Oct 2019 10:00:00 GMT A promising therapeutic innovation for creatine transporter deficiency. https://www.cea.fr/drf/joliot/en/Pages/news/Science/2019/therapeutic-innovation-creatine-transporter-deficiency.aspx ​Two teams from JOLIOT (SPI / SCBM), in collaboration with the University of Cincinnati, confirm the interest of a drug candidate to treat the congenital creatine deficiency syndrome, a rare neurological childhood disease, responsible for developmental delays and intellectual disability. The results obtained in an animal model of the disease show that it is possible to administer, nasally, dodecyl creatine ester-loaded microspheres, thus improving the cognitive functions of treated animals. Genetic diseases ; Pharmacology Scientific result Fri, 17 May 2019 10:00:00 GMT Pain: a promising toxin isolated from a spider venom https://www.cea.fr/drf/joliot/en/Pages/news/Science/2019/pain-promising-toxin-spider-venom.aspx A collaboration between SIMOPRO, Sanofi R & D, Smartox Laboratories and the Thorax Institute, has isolated a toxin with antinociceptive properties from a high-throughput electrophysiological screening of a collection of more than 100 venoms. Cyriotoxin-1a has been identified, sequenced, chemically synthesized and functionally characterized - from cell to organism in vivo. Pharmacology ; High-throughput screening SIMOPRO Scientific result antinociception;venoms;sodium channel;Pain; Mon, 11 Mar 2019 11:00:00 GMT An original biotechnological approach to create new bioactive molecules https://www.cea.fr/drf/joliot/en/Pages/news/Science/2018/biotechnological-approach-new-bioactive-molecules.aspx ​Muriel Gondry's Research Team (I2BC@Saclay / SBIGeM), in collaboration with SIMOPRO and Biomolecules Laboratory of the Sorbonne University's one, produced 200 cyclodipeptides containing non-natural amino acids by luring and diverting the cellular machinery for the synthesis of proteins. This unprecedented approach significantly increases the diversity of these bioactive molecules. Biotechnology ; Structural biology Scientific result Mon, 05 Mar 2018 11:00:00 GMT Ultrasound to improve drug delivery to the brain https://www.cea.fr/drf/joliot/en/Pages/news/Science/2018/ultrasound-drug-delivery-brain.aspx Researchers from NeuroSpin (Frédéric Joliot Institute/CEA) and MIRCen (François Jacob Institute/CEA Institute of Biology) have just developed an ultrasound device guided by magnetic resonance imaging (MRI) to increase temporarily and locally the vascular permeability in non-human primates, which could be used to effectively deliver drugs to the brain. Brain ; Health & life sciences ; Pharmacology Scientific result Mon, 19 Feb 2018 11:00:00 GMT Modulating cerebral cholesterol: a new avenue of research to treat Alzheimer’s disease? https://www.cea.fr/drf/joliot/en/Pages/ARCHIVES/I2BM_anglais/News/Scientific_news/Articles/2015/Modulating-cerebral-cholesterol-new-avenue-research-treat-Alzheimer.aspx Two French research teams have recently shown in a rodent model that overexpression of an enzyme capable of eliminating excess cholesterol in the brain can act in a beneficial way on the tau component of the disease to completely correct it. Alzheimer's disease ; Gene and cell therapy ; Biotechnology MIRcen Scientific result Mon, 14 Sep 2015 10:00:00 GMT A nano-drug for protecting neurons https://www.cea.fr/drf/joliot/en/Pages/ARCHIVES/IBITECS_anglais/News/2015/a-nano-drug-for-protecting-neurons.aspx A nano-drug has been developed for treating certain neurological diseases such as brain ischemia, as well as injuries to bone marrow. It is composed of a therapeutic molecule, adenosine, and the vector squalene, which allows it to circulate in the body and reach the areas to be treated. Brain ; Pharmacology IBITECS Scientific result Thu, 05 Mar 2015 11:00:00 GMT Bio-magnet for targeted medical imaging https://www.cea.fr/drf/joliot/en/Pages/ARCHIVES/I2BM_anglais/News/Scientific_news/Articles/2015/Bio-magnet-for-targeted-medical-imaging.aspx The CEA-IBEB has partnered with the CEA-I2BM to develop original MRI contrast agents. Nano-magnets produced by bacteria may reveal targets at the molecular level. Biotechnology ; Cell and molecular imaging ; MRI ; Diagnosis ; Nanomedicine LBC Scientific result Fri, 20 Feb 2015 11:00:00 GMT